Loading...
Market
How will pharmaceutical companies respond to mifepristone ruling by end of 2024?
5
Resolution / Starting Odds
Increase production • 33%
Maintain current levels • 33%
Decrease production • 33%
Company press releases, news reports
Story
U.S. Supreme Court Unanimously Upholds Access to Abortion Pill Mifepristone on June 13, 2024
Jun 13, 2024, 06:53 PM
On June 13, 2024, the U.S. Supreme Court has unanimously upheld access to the FDA-approved abortion pill, mifepristone, rejecting efforts to impose restrictions. This decision preserves access to a medication used in nearly two-thirds of all U.S. abortions. Despite this ruling, the broader fight over abortion rights continues, with some Republicans pushing for nationwide restrictions and bans. The court's decision leaves the FDA's approval of mifepristone intact but does not address future questions about abortion access.
View original story
Similar markets
Yes • 50%
No • 50%
Increase in support • 33%
Decrease in support • 33%
No significant change • 34%
Yes • 50%
No • 50%
Stop using Plavix • 33%
Continue using Plavix with warnings • 33%
No change in usage • 34%
Anti-abortion groups • 33%
Pro-abortion rights groups • 33%
Other • 34%
California • 25%
Texas • 25%
Florida • 25%
New York • 25%
Ninth Circuit • 25%
Fifth Circuit • 25%
DC Circuit • 25%
Other • 25%
Reformulate supply chains • 33%
Seek exemptions • 33%
Challenge the Act legally • 34%